Poly Medicure Limited POLYMED NIFTY_SMALLNSEPHARMA
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 19.1% over 5 years.
- Profit CAGR of 22.7% over 5 years.
CONS
- Trading 40.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | POLYMED Poly Medicure Limited NIFTY_SMALLNSEPHARMA | 1,349.70 | 42.55 | ₹13,696.69 Cr | 0.26% | 13.33% | 10.85% | 19.15% | 22.71% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 440.83 Cr | 403.21 Cr | 443.88 Cr | 493.66 Cr | 534.51 Cr |
| Cost of Revenue | - | - | 148.15 Cr | 127.23 Cr | 135.66 Cr | 312.54 Cr | 178.16 Cr |
| Gross Profit | - | - | 292.68 Cr | 275.98 Cr | 308.22 Cr | 181.12 Cr | 356.35 Cr |
| Operating Expenses | - | - | 194.25 Cr | 193.10 Cr | 218.47 Cr | 255.47 Cr | 284.18 Cr |
| Operating Income | - | - | 98.43 Cr | 82.88 Cr | 89.75 Cr | -74.35 Cr | 72.17 Cr |
| EBITDA | - | - | 146.18 Cr | 149.15 Cr | 149.59 Cr | 132.33 Cr | 129.86 Cr |
| Interest Expense | - | - | 2.17 Cr | 2.95 Cr | 2.97 Cr | 5.96 Cr | 6.41 Cr |
| Pretax Income | - | - | 122.85 Cr | 122.95 Cr | 121.69 Cr | 97.61 Cr | 85.22 Cr |
| Tax Provision | - | - | 31.02 Cr | 29.86 Cr | 29.89 Cr | 26.80 Cr | 20.18 Cr |
| Net Income | - | - | 91.83 Cr | 93.08 Cr | 91.83 Cr | 70.93 Cr | 65.04 Cr |
| Diluted EPS | - | - | 8.92 | 9.17 | 9.06 | 6.99 | 6.53 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,108.66 Cr | 1,365.69 Cr | 1,669.83 Cr | 1,875.26 Cr |
| Cost of Revenue | - | 509.32 Cr | 604.32 Cr | 555.44 Cr | 596.81 Cr |
| Gross Profit | - | 599.34 Cr | 761.38 Cr | 1,114.39 Cr | 1,278.45 Cr |
| Operating Expenses | - | 381.49 Cr | 458.72 Cr | 744.18 Cr | 951.65 Cr |
| Operating Income | - | 217.85 Cr | 302.65 Cr | 370.20 Cr | 326.80 Cr |
| EBITDA | - | 303.20 Cr | 418.89 Cr | 547.69 Cr | 561.28 Cr |
| Interest Expense | - | 8.54 Cr | 10.70 Cr | 12.00 Cr | 18.29 Cr |
| Pretax Income | - | 237.49 Cr | 344.27 Cr | 452.52 Cr | 427.47 Cr |
| Tax Provision | - | 58.21 Cr | 86.01 Cr | 113.96 Cr | 96.18 Cr |
| Net Income | - | 179.28 Cr | 258.26 Cr | 338.56 Cr | 331.29 Cr |
| Diluted EPS | 15.27 | 18.67 | 26.90 | 34.11 | - |
Compounded Sales Growth
| 5 Years: | 19.15% |
| 1 Year: | 21.30% |
Compounded Profit Growth
| 5 Years: | 22.71% |
| 1 Year: | -26.80% |
Stock Price Performance
| 1 Year: | -40.82% |
| 6 Months: | -29.29% |
| 3 Months: | +4.86% |
| 1 Month: | -10.74% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 1,577.21 Cr | 1,858.67 Cr | 3,192.45 Cr | 3,918.57 Cr |
| Current Assets | - | 806.69 Cr | 841.60 Cr | 1,917.00 Cr | 1,941.73 Cr |
| Cash & Equivalents | - | 7.06 Cr | 12.05 Cr | 8.70 Cr | 51.23 Cr |
| Inventory | - | 208.65 Cr | 221.03 Cr | 285.57 Cr | 433.84 Cr |
| Receivables | - | 235.43 Cr | 269.94 Cr | 349.73 Cr | 531.17 Cr |
| Total Liabilities | - | 335.58 Cr | 388.62 Cr | 426.79 Cr | 769.32 Cr |
| Current Liabilities | - | 293.30 Cr | 351.21 Cr | 370.17 Cr | 575.52 Cr |
| Long Term Debt | - | 17.50 Cr | 84.05 L | 0 | 52.09 Cr |
| Total Debt | - | 149.02 Cr | 173.90 Cr | 180.25 Cr | 353.58 Cr |
| Total Equity | - | 1,241.63 Cr | 1,470.05 Cr | 2,765.66 Cr | 3,106.17 Cr |
| Shares Outstanding | - | 9.59 Cr | 9.60 Cr | 10.13 Cr | 10.14 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 191.05 Cr | 266.08 Cr | 233.05 Cr | 246.37 Cr |
| Investing Cash Flow | - | -179.24 Cr | -240.94 Cr | -1,187.18 Cr | -225.38 Cr |
| Financing Cash Flow | - | -12.51 Cr | -20.15 Cr | 950.51 Cr | 20.15 Cr |
| Capital Expenditure | - | -239.27 Cr | -277.02 Cr | -331.03 Cr | -308.39 Cr |
| Free Cash Flow | - | -48.22 Cr | -10.93 Cr | -97.98 Cr | -62.02 Cr |
| Net Change in Cash | - | -69.49 L | 4.99 Cr | -3.63 Cr | 41.14 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 54.1% | 55.8% | 66.7% | 68.2% |
| Operating Margin % | - | 19.6% | 22.2% | 22.2% | 17.4% |
| Net Margin % | - | 16.2% | 18.9% | 20.3% | 17.7% |
| ROE % | - | 14.4% | 17.6% | 12.2% | 10.7% |
| ROCE % | - | 17.0% | 20.1% | 13.1% | 9.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for POLYMED